Further investigation of dopamine degeneration in LLD may inform the development of treatments for executive function, apathy and anxiety, disabling symptoms that typically persist after depression remission, as well as of biomarkers to identify LLD patients at risk of PD
HOW IT WORKS From first visit to visible results
Turn the vial and syringe upside down so the needle points upward, and pull back on the plunger to withdraw the correct amount of medication
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
A lack of sufficient glutathione can hinder the bodys ability to repair itself effectively during sleep
